Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr-Jun;18(2):238-240.
doi: 10.4183/aeb.2022.238.

131I SUCCESSFULLY TREATED A CASE OF HYPERTHYROIDISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

J Ge  1 , J Wang  2 , H Liu  3 , R Wan  1 , X Yao  1
Affiliations
Case Reports

131I SUCCESSFULLY TREATED A CASE OF HYPERTHYROIDISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

J Ge et al. Acta Endocrinol (Buchar). 2022 Apr-Jun.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for various types of hereditary hematologic disease, hematological malignancy, primary immunodeficiency and metabolic disease. Thyroid dysfunction is a common complication of HSCT, which situation is mainly manifested as hypothyroidism and rarely as hyperthyroidism. This report presents a 28-year-old man who developed hyperthyroidism 9 years after sibling allogeneic HSCT, which was most likely caused by chronic GVHD. In the meantime, the patient also suffered from liver dysfunction and pancytopenia, for which he was inappropriate to take antithyroid drugs (ATD) for treatment of hyperthyroidism. The patient was orally administered 259 MBq 131I, an individualized dose. The symptoms of hyperthyroidism were mitigated by 131I treatment.

Keywords: 131I; Hematopoietic Stem Cell Transplantation; Hyperthyroidism; graft versus host disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest. Funding Sources This work was supported by“the Fundamental Research Funds for the Central Universities”(grant numbers WK9110000192).

Similar articles

See all similar articles

References

    1. Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Di Somma C, Orio F, Palomba S, Lombardi G, Rotoli B, Colao A. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med. 2005;118(6):664–670. - PubMed
    1. Sağ E, Gönç N, Alikaşifoğlu A, Kuşkonmaz B, Uçkan D, Özön A, Kandemir N. Hyperthyroidism After Allogeneic Hematopoietic Stem Cell Transplantation: A Report of Four Cases. J Clin Res Pediatr Endocrinol. 2015;7(4):349–354. - PMC - PubMed
    1. Isshiki Y, Ono K, Shono K, Onoda M, Yokota A. Autoimmune thyroid dysfunction after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2016;57(5):1227–1229. - PubMed
    1. Au WY, Lie AK, Kung AW, Liang R, Hawkins BR, Kwong YL. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(4):383–388. - PubMed
    1. Oka S, Ono K, Nohgawa M. Cytomegalovirus reactivation triggers the late onset of hyperthyroidism after autologous peripheral blood transplantation. Leuk Res Rep. 2018;11:5–7. Published 2018. - PMC - PubMed

Publication types

LinkOut - more resources